EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2768-2778

  Fukai, Junya ^a,b   Yokote, Hideyuki ^b,d   Yamanaka, Ryuya ^c   Arao, Tokuzo ^d   Nishio, Kazuto ^b,d   Itakura, Toru ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A4; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN CDC42; PROTEIN KINASE B; RAC1 PROTEIN;

ARTICLE; BRAIN TISSUE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME ACTIVATION; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MEMBRANE PROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RAC1 GTP-BINDING PROTEIN; RECEPTOR, EPHA4; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 54049153684     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2263     Document Type: Article

References (50)

1. Murai KK, Pasquale EB. 'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci 2003;116:2823-32.
2. Eph Nomenclature Committee. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 1997;90:403-4.
3. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005;6:462-75.
4. Pasquale EB. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci 2004;7:417-8.
5. Henkemeyer M, Orioli D, Henderson JT, et al. Nuk controls pathfinding of commissural axons in the mammalian central nervous system. Cell 1996;86:35-46.
6. Kullander K, Croll SD, Zimmer M, et al. Ephrin-B3 is the midline barrier that prevents corticospinal tract axons from recrossing, allowing for unilateral motor control. Genes Dev 2001;15:877-88.
7. Frisen J, Holmberg J, Barbacid M. Ephrins and their Eph receptors: multitalented directors of embryonic development. EMBO J 1999;18:5159-65.
8. Lai KO, Ip FC, Cheung J, et al. Expression of Eph receptors in skeletal muscle and their localization at the neuromuscular junction. Mol Cell Neurosci 2001;17:1034-47.
9. Gerlai R. Eph receptors and neural plasticity. Nat Rev Neurosci 2001;2:205-9.
10. Oike Y, Ito Y, Hamada K, et al. Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells. Blood 2002;100:1326-33.
11. Adams RH, Wilkinson GA, Weiss C, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999;13:295-306.
12. Easty DJ, Hill SP, Hsu MY, et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999;84:494-501.
13. Vogt T, Stolz W, Welsh J, et al. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 1998;4:791-7.
14. Kiyokawa E, Takai S, Tanaka M, et al. Overexpression of ER K, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 1994;54:3645-50.
15. Tang XX, Zhao H, Robinson ME, et al. Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A 2000;97:10936-41.
16. Walker-Daniels J, Coffman K, Azimi M, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999;41:275-80.
17. Miyazaki T, Kato H, Fukuchi M, et al. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 2003;103:657-63.
18. Surawska H, Ma PC, Salgia R, The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004;15:419-33.
19. Carles-Kinch K, Kilpatrick KE, Stewart JC, et al. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002;62:2840-7.
20. Nakada M, Niska JA, Miyamori H, et al. The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res 2004;64:3179-85.
21. Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-7.
22. Ong SH, Guy GR, Hadari YR, et al. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol 2000;20:979-89.
23. Hadari YR, Kouhara H, Lax I, et al. Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol Cell Biol 1998;18:3966-73.
24. Schumacher S, Gryzik T, Tannebaum S, et al. The RhoGEF Pebble is required for cell shape changes during cell migration triggered by the Drosophila FGF receptor Heartless. Development 2004;131:2631-40.
25. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-37.
26. Yamaguchi F, Saya H, Bruner JM, et al. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci U S A 1994;91:484-8.
27. Morrison RS, Yamaguchi F, Saya H, et al. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol 1994;18:207-16.
28. Yamada SM, Yamaguchi F, Brown R, et al. Suppression of glioblastoma cell growth following antisense oligonucleotide-mediated inhibition of fibroblast growth factor receptor expression. Glia 1999;28:66-76.
29. Kleihues P, Cavenee WK. WHO classification. Tumours of the nervous system. IARC Press; 2000. p. 27-39.
30. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
31. Yamanaka R, Arao T, Yajima N, et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006;25:5994-6002.
32. Yokote H, Fujita K, Jing X, et al. Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proc Natl Acad Sci U S A 2005;102:18866-71.
33. Wang W, Zhu NL, Chua J, et al. Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. J Neurosurg 2005;103:1058-66.
34. Bruce V, Olivieri G, Eickelberg O, et al. Functional activation of EphA5 receptor does not promote cell proliferation in the aberrant EphA5 expressing human glioblastoma U-118 MG cell line. Brain Res 1999;821:169-76.
35. Nakada M, Niska JA, Tran NL, et al. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 2005;167:565-76.
36. Wykosky J, Gibo DM, Stanton C, et al. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 2005;3:541-51.
37. Nakada M, Drake KL, Nakada S, et al. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 2006;66:8492-500.
38. Kullander K, Butt SJ, Lebret JM, et al. Role of EphA4 and EphrinB3 in local neuronal circuits that control walking. Science 2003;299:1889-92.
39. Iwasato T, Katoh H, Nishimaru H, et al. Rac-GAP α-chimerin regulates motor-circuit formation as a key mediator of EphrinB3/EphA4 forward signaling. Cell 2007;130:742-53.
40. Miao H, Wei BR, Peehl DM, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001;3:527-30.
41. Elowe S, Holland SJ, Kulkarni S, et al. Downregulation of the Rasmitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol 2001;21:7429-41.
42. Kim I, Ryu YS, Kwak HJ, et al. EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J 2002;16:1126-8.
43. Tong J, Elowe S, Nash P, et al. Manipulation of EphB2 regulatory motifs and SH2 binding sites switches MAPK signaling and biological activity. J Biol Chem 2003;278:6111-9.
44. Aoki M, Yamashita T, Tohyama M. EphA receptors direct the differentiation of mammalian neural precursor cells through a mitogen-activated protein kinase-dependent pathway. J Biol Chem 2004;279:32643-50.
45. Vindis C, Cerretti DP, Daniel TO, et al. EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis. J Cell Biol 2003;162:661-71.
46. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-35.
47. Shamah SM, Lin MZ, Goldberg JL, et al. EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell 2001;105:233-44.
48. Parney IF, Chang SM. Current chemotherapy for glioblastoma. Cancer J 2003;9:149-56.
49. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2. PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 2004;4:105-28.
50. Korfee S, Gauler T, Hepp R, et al. New targeted treatments in lung cancer - overview of clinical trials. Lung Cancer 2004;45 Suppl 2:S199-208.